Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.

Abstract

Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.

Cite this paper

@article{Oliveira2010PositiveRT, title={Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.}, author={G A P Oliveira and Elaine S. Costa and Maria Silvia Freitas and Fabiano Ferreira Dutra and Simone F. Maia and Marcelo C Guerra and Mar{\'i}a Dolores Tabernero and Rajka Borojevic and Ivone Beatriz Otazu and Jarques L{\'u}cio Silva}, journal={Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas}, year={2010}, volume={43 6}, pages={580-4} }